Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Glycine, Threonine, Sodium chloride, Sodium dihydrogen phosphate dihydrate, Tryptophan, Calcium chloride dihydrate, Methionine, Zinc acetate dihydrate, Glucose monohydrate, Magnesium acetate tetrahydrate, Potassium acetate, Sodium acetate trihydrate, Soya bean oil, refined, Alanine, Arginine, Aspartic acid, Glutamic acid, Isoleucine, Leucine, Phenylalanine, Proline, Serine, Valine, Lysine hydrochloride, Medium-chain triglycerides, Histidine hydrochloride monohydrate, Sodium hydroxide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Lipoflex peri contains fluids and substances called amino acids, electrolytes and fatty acids that are essential for the body to grow or to recover. It also contains calories in the form of carbohydrates and fats. You are given this medicine when you are unable to eat food normally. There are many situations when this might be the case, for example when you are recovering from surgery, injuries or burns, or when you are unable to absorb food from your stomach and gut. This emulsion can be given to adults, adolescents and children over 2 years of age. 2.
e Lipoflex peri
Do not use Lipoflex peri ● if you are allergic to any of the active substances, to egg, peanut or soybean or to any of the other ingredients of this medicine (listed in section 6). ● This medicine must not be given to newborn infants, infants and toddlers under two years old. Also, do not use this medicine if you suffer from any of the following: ● life-threatening blood circulation problems such as those that can occur if you are in a state of collapse or shock ● heart attack or stroke ● severely impaired blood clotting function, bleeding risk (severe coagulopathy, aggravating haemorrhagic diatheses) ● blocking of blood vessels by blood clots or fat (embolism) ● severe liver failure ● impaired bile flow (intrahepatic cholestasis) ● severe kidney failure in the absence of kidney replacement therapy ● disturbances of your body salt composition
● ● ● ●
fluid deficit or excess water in your body water on your lungs (pulmonary oedema) severe heart failure certain metabolic disorders such as
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Lipoflex peri. Please inform your doctor if: ● you have heart, liver or kidney problems ● you suffer from certain types of metabolic disorders such as diabetes, abnormal blood fat values and disorders of your body fluid and salt composition or your acid-base balance. You will be monitored closely to detect early signs of an allergic reaction (such as fever, shivering, rash, or shortness of breath) when you receive this medicine. Further monitoring and tests such as various examinations of blood samples will be applied to make sure that your body handles the administered foodstuffs properly. The nursing staff may also take measures to ensure that your body's fluid and electrolyte requirements are met. In addition to this medicine you may receive further nutrients (foodstuffs) in order to fully cover your requirements. Children This medicine must not be given to newborn infants, infants and toddlers under two years old. Other medicines and Lipoflex peri Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Lipoflex peri can interact with some other medicines. Please tell your doctor, pharmacist or nurse if you are taking or receiving any of the following: ● insulin ● heparin ● medicines that prevent undesirable blood clotting such as warfarin or other coumarin derivatives ● medicines to promote urine flow (diuretics) ● medicines to treat high blood pressure (ACE inhibitors) ● medicines to treat high blood pressure or heart problems (angiotensin-II-receptor antagonists) ● medicines used in organ transplants such as ciclosporin and tacrolimus ● medicines to treat inflammation (corticosteroids) ● hormone preparations that affect your fluid balance (adrenocorticotropic hormone or ACTH)
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, you will receive this medicine only if the doctor or pharmacist considers it absolutely necessary for your recovery. There is no data available about the use of Lipoflex peri in pregnant women. Breast-feeding is not recommended for mothers on parenteral nutrition. Nutriflex Lipid peri contains sodium This medicine contains 1150 mg sodium (main component of cooking/table salt) in each 1250 ml bag. This is equivalent to 58% of the recommended maximum daily dietary intake of sodium for an adult. Talk to your doctor or pharmacist if you need one or more bags daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.
Driving and using machines This medicine is normally given to immobile patients, e.g. in a hospital or clinic which would exclude driving or using machines. However, this medicine has no effect on the ability to drive or use machines. Lipoflex peri contains sodium This medicine contains 1150 mg sodium (main component of cooking/table salt) in each 1250 ml bag. This is equivalent to 58% of the recommended maximum daily dietary intake of sodium for an adult. The maximum recommended daily dose of this medicinal product contains 2580 mg sodium (found in table salt). This is equivalent to 129% of the adult recommended maximum daily dietary intake for sodium. Talk to your doctor or pharmacist if you need one or more bags daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.
3.
Lipoflex peri
This medicine is administered by intravenous infusion (drip), that is, through a small tube directly into a vein. This medicine can be administered through one of your smaller (peripheral) or larger (central) veins. Your doctor or pharmacist will decide how much of this medicine you need and for how long you will require treatment with this medicine. Use in children This medicine must not be given to newborn infants, infants and toddlers under two years old. Your doctor will decide how much of this medicine your child needs and for how long your child will require treatment with this medicine. If you use more Lipoflex peri than you should
If you have received too much of this medicine you may suffer from a so-called 'overload syndrome' and the following symptoms: ● fluid excess and electrolyte disorders ● water on your lungs (pulmonary oedema) ● loss of amino acids through the urine and disturbed amino acid balance ● vomiting, feeling sick ● shivering ● high blood sugar level ● glucose in the urine ● fluid deficit ● blood much more concentrated than normal (hyperosmolality) ● impairment or loss of consciousness due to extremely high blood sugar ● enlargement of the liver (hepatomegaly) with and without jaundice (icterus) ● enlargement of the spleen (splenomegaly) ● fat deposition in the inner organs ● abnormal values of liver function tests ● reduction of red blood cell count (anaemia) ● reduction of white blood cell count (leucopenia) ● reduction of blood platelet count (thrombocytopenia) ● increase of immature red blood cells (reticulocytosis) ● rupture of blood cells (haemolysis) ● bleeding or a tendency to bleeding ● impairment of blood coagulation (as can be seen by changes of bleeding time, coagulation time, prothrombin time etc.) ● fever ● high blood fat levels ● loss of consciousness If any of these symptoms occur, the infusion must be stopped immediately. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may be serious. If any of the following side effects occur, tell your doctor immediately, he will stop giving you this medicine: Rare (may affect up to 1 in 1,000 people): ● allergic reactions, for example skin reactions, shortness of breath, swelling of the lips, mouth, and throat, difficulty breathing Other side effects include: Common (may affect up to 1 in 10 people): ● irritation or inflammation of veins (phlebitis, thrombophlebitis) Uncommon (may affect up to 1 in 100 people): ● feeling sick, vomiting, loss of appetite
Rare (may affect up to 1 in 1,000 people): ● increased tendency for your blood to clot ● bluish discolouration of the skin ● shortness of breath ● headache ● flushing ● reddening of skin (erythema) ● sweating ● chills ● feeling cold ● high body temperature ● drowsiness ● pain in the chest, back, bones or lumbar region ● decrease or increase in blood pressure Very rare (may affect up to 1 in 10,000 people): ● abnormally high blood fat or blood sugar values ● high levels of acidic substances in your blood ● Too much lipid can lead to fat overload syndrome, for more information on this please see under the heading "If you use more Lipoflex peri than you should" in section 3. Symptoms normally disappear when the infusion is stopped. Not known (frequency cannot be estimated from the available data): ● reduction of white blood cell count (leucopenia) ● reduction of blood platelet count (thrombocytopenia) ● impaired bile flow (cholestasis) Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
Lipoflex peri
Keep this medicine out of the sight and reach of children. Do not store above 25 °C. Do not freeze. If accidentally frozen, discard the bag. Keep the bag in the protective overwrap in order to protect from light. Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month. 6.
What Lipoflex peri contains The active substances in the ready-for-use mixture are: from the top chamber (glucose solution) Glucose monohydrate
in 1000 ml
in 1250 ml
in 1875 ml
in 2500 ml
70.40 g
88.00 g
132.0 g
176.0 g
equivalent to glucose Sodium dihydrogen phosphate dihydrate Zinc acetate dihydrate
64.00 g 0.936 g
80.00 g 1.170 g
120.0 g 1.755 g
160.0 g 2.340 g
5.280 mg
6.600 mg
9.900 mg
13.20 mg
from the middle chamber (fat emulsion) Soya-bean oil, refined Medium-chain triglycerides
in 1000 ml
in 1250 ml
in 1875 ml
in 2500 ml
20.00 g 20.00 g
25.00 g 25.00 g
37.50 g 37.50 g
50.00 g 50.00 g
from the bottom chamber (amino acid solution) Isoleucine Leucine Lysine hydrochloride equivalent to lysine Methionine Phenylalanine Threonine Tryptophan Valine Arginine Histidine hydrochloride monohydrate equivalent to histidine Alanine Aspartic acid Glutamic acid Glycine Proline Serine Sodium hydroxide Sodium chloride Sodium acetate trihydrate Potassium acetate Magnesium acetate tetrahydrate Calcium chloride dihydrate
in 1000 ml
in 1250 ml
in 1875 ml
in 2500 ml
1.872 g 2.504 g 2.272 g 1.818 g 1.568 g 2.808 g 1.456 g 0.456 g 2.080 g 2.160 g 1.352 g
2.340 g 3.130 g 2.840 g 2.273 g 1.960 g 3.510 g 1.820 g 0.570 g 2.600 g 2.700 g 1.690 g
3.510 g 4.695 g 4.260 g 3.410 g 2.940 g 5.265 g 2.730 g 0.855 g 3.900 g 4.050 g 2.535 g
4.680 g 6.260 g 5.680 g 4.546 g 3.920 g 7.020 g 3.640 g 1.140 g 5.200 g 5.400 g 3.380 g
1.000 g 3.880 g 1.200 g 2.800 g 1.320 g 2.720 g 2.400 g 0.640 g 0.865 g 0.435 g 2.354 g 0.515 g 0.353 g
1.251 g 4.850 g 1.500 g 3.500 g 1.650 g 3.400 g 3.000 g 0.800 g 1.081 g 0.544 g 2.943 g 0.644 g 0.441 g
1.876 g 7.275 g 2.250 g 5.250 g 2.475 g 5.100 g 4.500 g 1.200 g 1.622 g 0.816 g 4.415 g 0.966 g 0.662 g
2.502 g 9.700 g 3.000 g 7.000 g 3.300 g 6.800 g 6.000 g 1.600 g 2.162 g 1.088 g 5.886 g 1.288 g 0.882 g
Electrolytes Sodium Potassium Magnesium Calcium Zinc
in 1000 ml 40 mmol 24 mmol 2.4 mmol 2.4 mmol 0.024 mmol 38 mmol 32 mmol 6.0 mmol
in 1250 ml 50 mmol 30 mmol 3.0 mmol 3.0 mmol 0.03 mmol
in 1875 ml 75 mmol 45 mmol 4.5 mmol 4.5 mmol 0.045 mmol
in 2500 ml 100 mmol 60 mmol 6.0 mmol 6.0 mmol 0.06 mmol
48 mmol 40 mmol 7.5 mmol
72 mmol 60 mmol 11.25 mmol
96 mmol 80 mmol 15.0 mmol
Chloride Acetate Phosphate
Amino acid content Nitrogen content Carbohydrate content Lipid content Energy in the form of lipids Energy in the form of carbohydrates Energy in the form of amino acids Non-protein energy Total energy
Osmolality Theoretical osmolarity pH
32 g 4.6 g 64 g 40 g
40 g 5.7 g 80 g 50 g
60 g 8.6 g 120 g 75 g
80 g 11.4 g 160 g 100 g
1590 kJ (380 kcal) 1075 kJ (255 kcal) 535 kJ (130 kcal) 2665 kJ (635 kcal) 3200 kJ (765 kcal)
1990 kJ (475 kcal) 1340 kJ (320 kcal) 670 kJ (160 kcal) 3330 kJ (795 kcal) 4000 kJ (955 kcal)
2985 kJ (715 kcal) 2010 kJ (480 kcal) 1005 kJ (240 kcal) 4995 kJ (1195 kcal) 6000 kJ (1435 kcal)
3980 kJ (950 kcal) 2680 kJ (640 kcal) 1340 kJ (320 kcal) 6660 kJ (1590 kcal) 8000 kJ (1910 kcal)
950 950 mOsm/kg 950 mOsm/kg 950 mOsm/kg mOsm/kg 840 840 mOsm/l 840 mOsm/l 840 mOsm/l mOsm/l 5.0 – 6.0 5.0 – 6.0 5.0 – 6.0 5.0 – 6.0
The other ingredients are citric acid monohydrate (for pH adjustment), egg phospholipids for injection, glycerol, sodium oleate, all-rac-alpha-tocopherol and water for injections. What Lipoflex peri looks like and contents of the pack The ready-to-use product is an emulsion for infusion, i.e. it is administered through a small tube into a vein. Lipoflex peri is supplied in flexible multichamber bags containing: – 1250 ml (500 ml of amino acids solution + 250 ml of fat emulsion + 500 ml of glucose solution) – 1875 ml (750 ml of amino acids solution + 375 ml of fat emulsion + 750 ml of glucose solution) – 2500 ml (1000 ml of amino acids solution + 500 ml of fat emulsion + 1000 ml of glucose solution)
Figure A
Figure B
Figure A: The multichamber bag is packed in a protective overwrap. An oxygen absorber and an oxygen indicator are placed between the bag and the overwrap; the oxygen absorber sachet is made of inert material and contains iron hydroxide. Figure B: The top chamber contains a glucose solution, the middle chamber contains a fat emulsion, and the bottom chamber contains an amino acid solution. The glucose and the amino acid solutions are clear and colourless or straw-coloured. The fat emulsion is milkywhite. The top chamber and the middle chamber can be connected with the bottom chamber by opening the intermediate seams (peel seams). The design of the bag permits mixing of the amino acids, glucose, lipids and electrolytes in a single chamber. Opening the peel seams results in sterile mixing to form an emulsion. The different container sizes are presented in cartons containing five bags. Pack sizes: 5 x 1250 ml, 5 x 1875 ml and 5 x 2500 ml Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer B. Braun Melsungen AG Carl-Braun-Str. 1 34212 Melsungen, Germany
Postal address: 34209 Melsungen, Germany
Tel.: +49-(0)-5661-71-0 Fax: +49-(0)-5661-71-4567 This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (GB and NI) under the following names: Austria Nutriflex Lipid peri B.Braun Emulsion zur Infusion Belgium Nutriflex Lipid peri, 32 g/l Amino + 64 g/l G , emulsie voor infusie Denmark Lipoflex peri Finland Nutriflex Lipid 32/64/40 perifer infuusioneste, emulsio Germany NuTRIflex Lipid peri novo Emulsion zur Infusion Iceland Nutriflex Lipid 32/64 peri innrennslislyf, fleyti Italy LIPOFLEX AA32/G64 Emulsione per infusione Luxembourg NuTRIflex Lipid peri novo Emulsion zur Infusion Netherlands Nutriflex Lipid peri, 32 g/l Amino + 64 g/l G, emulsie voor infusie Norway Lipoflex peri infusjonsvæske, emulsjon Poland Lipoflex peri Romania NuTRIflex Lipid peri novo, emulsie perfuzabilă Spain Lipoflex peri emulsión para perfusión EFG Sweden Nutriflex Lipid 32/64/40 perifer infusionsvätska, emulsion United Kingdom (GB and NI) Lipoflex peri emulsion for infusion This leaflet was last revised in 09/2023 ______________________________________________________________________________ The following information is intended for healthcare professionals only:
No special requirements for disposal. Parenteral nutrition products should be visually inspected for damage, discolouration and emulsion instability before use. Do not use bags which are damaged. Overwrap, primary bag and the peel seams between the chambers should be intact. Only use if the amino acid and glucose solutions are clear and colourless up to straw-coloured and the lipid emulsion is homogenous with milky white appearance. Do not use if the solutions contain particulate matter. After mixing the three chambers, do not use if the emulsion shows discolouration or signs of phase separation (oil drops, oil layer). Stop the infusion immediately in case of discolouration of the emulsion or signs of phase separation. Before opening the overwrap, check the colour of the oxygen indicator (see Figure A). Do not use if the oxygen indicator turned pink. Use only if the oxygen indicator is yellow. Preparation of the mixed emulsion Strict adherence to aseptic handling principles must be complied with. To open: Tear overwrap starting from the tear notches (Fig. 1). Remove the bag from its protective overwrap. Discard overwrap, oxygen indicator, and oxygen absorber.
Visually inspect the primary bag for leaks. Leaky bags must be discarded, since the sterility cannot be guaranteed. Mixing of the bag and additions of additives To open and mix the chambers sequentially, roll the bag with both hands, starting first by opening the peel seam that separates the top chamber (glucose) and the bottom chamber (amino acids) (Fig. 2).
After removing the aluminium seal (Fig. 3) one can add compatible water-soluble additives via the medication port (Fig. 4) to the clear aqueous solutions. Mix the contents thoroughly (Fig. 5) and visually inspect the mixture for precipitations (Fig. 6). Only clear solution must be used.
Then continue applying pressure so that the peel seam separating the middle chamber (lipids) and the bottom chamber opens (Fig. 7). The mixture is a milky white homogenous oil-in-water emulsion. After all chambers are mixed one can add compatible additives via the medication port (Fig. 4). Mix the contents thoroughly (Fig. 8) and visually inspect the mixture (Fig. 9).
Compatibility data for different additives (e.g. electrolytes, trace elements, vitamins) and the corresponding shelf life of such admixtures can be provided on demand by the manufacturer. Preparation for infusion The emulsion should always be brought to room temperature prior to infusion. Remove the aluminium foil (Fig. 10) from the infusion port and attach the infusion set (Fig. 11). Use a nonvented infusion set or close the air vent when using a vented set. Hang the bag on an infusion stand (Fig. 12) and carry out infusion using the standard technique.
For single use only. Container and unused residues must be discarded after use. Do not reconnect partially used containers. If filters are used they must be lipid-permeable (pore size ≥ 1.2 μm). Shelf life after removing the protective overwrap and after mixing of contents of the bag Chemical and physicochemical in-use stability of the mixture of amino acids, glucose and fat was demonstrated for 7 days at 2-8 °C and additional 2 days at 25 °C. Shelf life after admixture of compatible additives From a microbiological point of view, the product should be used immediately after admixture of additives. If not used immediately after admixture of additives, in-use storage times and conditions prior to use are the responsibility of the user. The emulsion is to be used immediately after opening of the container. The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h. This medicinal product must not be mixed with other medicinal products for which compatibility has not been documented. This medicinal product should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination. .
Lipoflex peri emulsion for infusion comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Lipoflex peri emulsion for infusion is glycine, threonine, sodium chloride, sodium dihydrogen phosphate dihydrate, tryptophan, calcium chloride dihydrate, methionine, zinc acetate dihydrate, glucose monohydrate, magnesium acetate tetrahydrate, potassium acetate, sodium acetate trihydrate, soya bean oil, refined, alanine, arginine, aspartic acid, glutamic acid, isoleucine, leucine, phenylalanine, proline, serine, valine, lysine hydrochloride, medium-chain triglycerides, histidine hydrochloride monohydrate, sodium hydroxide.
Medicines with the same active substance, strength and form include: Lipoflex plus emulsion for infusion, Lipoflex special emulsion for infusion. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Lipoflex peri emulsion for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Supply of energy, essential fatty acids, amino acids, electrolytes and fluids for parenteral nutrition of patients in states of mild to moderately severe catabolism when oral or enteral nutrition is impossible, insufficient or contraindicated.
Lipoflex peri is indicated in adults, adolescents and children older than two years.
Posology
The dosage should be adapted to the patients' individual requirements.
It is recommended that this medicinal product be administered continuously. A stepwise increase of the infusion rate over the first 30 minutes up to the desired infusion rate avoids possible complications.
Adults
The maximum daily dose amounts to 40 ml/kg body weight, corresponding to:
1.28 g amino acids /kg body weight per day
2.56 g glucose /kg body weight per day
1.6 g lipid /kg body weight per day.
The maximum rate of infusion is 2.5 ml/kg body weight per hour, corresponding to:
0.08 g amino acids /kg body weight per hour
0.16 g glucose /kg body weight per hour
0.1 g lipid /kg body weight per hour.
For a patient weighing 70 kg this corresponds to a maximum infusion rate of 175 ml per hour. The amount of substrate administered is then 5.6 g of amino acids per hour, 11.2 g of glucose per hour and 7 g of lipids per hour.
Paediatric population
Newborn infants, infants and toddlers less than two years of age
Lipoflex peri is contraindicated in newborn infants, infants and toddlers < 2 years of age in whom the amino acid cysteine may be considered conditionally essential (see section 4.3).
Children from 2-18 years of age
No clinical studies were performed in the paediatric population.
This medicinal product can provide only a basic nutrient and energy supply to the paediatric patients.
Depending on the individual need Carnitine supplementation may be considered in paediatric patients expected to receive PN for more than 4 weeks.
The exact dosage depends on the patient's energy expenditure and the ability to metabolize the active ingredients of this medicinal product and therefore, should be individually adapted according to age, body weight, clinical condition and underlying disease.
Due to the individual needs of paediatric patients, this medicinal product may not cover sufficiently the total energy, nutrient, electrolyte and fluid requirements.
In such cases additional amino acids, carbohydrates and/or lipids, minerals and/or fluids must be provided in addition, as appropriate.
For calculation of dosage account must be taken of the hydration status of the paediatric patient.
The bag size should be chosen accordingly.
In addition, the daily fluid, glucose and energy requirements decrease with age. Thus, two age groups, from 2 to 12 years and 12 to 18 years, are considered.
Maximum daily dose
According to the paediatric guidelines the dose depends not only on age but also on the medical condition (acute, stable and recovery phase) of the paediatric patient.
For Lipoflex peri in the age group 2 to 12 years the magnesium concentration is the limiting factor for the maximum daily dose in all medical conditions.
For patients from 12 to 18 years the glucose concentration becomes the limiting factor in the acute phase while in the stable and recovery phase the magnesium concentration is limiting.
The resulting maximum daily doses are given in the table below.
2 to 12 years
12 to 18 years
Recommended
Lipoflex peri
Recommended
Lipoflex peri
Acute phase
Stable
Phase
Recovery phase
Acute phase
Stable Phase
Recovery phase
Maximum daily dose [ml/kg/d]
41.5
21.5
41.5
corresponding to
corresponding to
Fluids [ml/kg/d]
60 - 100
41.5
50 - 70
21.5
41.5
Amino acids [g/kg/d]
1.0 - 2.0 (2.5)
1.33
1.0 - 2.0
0.69
1.33
Glucose [g/kg/d]
Acute phase
1.4 – 3.6
2.66
0.7 – 1.4
1.38
-
Stable phase
2.2 – 5.8
1.4 – 2.9
-
2.66
Recovery phase
4.3 – 8.6
2.9 – 4.3
-
Lipids [g/kg/d]
≤ 3
1.66
≤ 3
0.86
1.66
Energy [kcal/kg/d]
Acute phase
30 - 45
31.7
20 - 30
16.4
-
Stable phase
40 - 60
25 - 40
-
31.7
Recovery phase
55 - 75
30 - 55
-
Sodium [mmol/kg/d]
1 - 3
1.66
1 - 3
0.86
1.66
Potassium [mmol/kg/d]
1 - 3
1.0
1 - 3
0.52
1.0
Calcium [mmol/kg/d]
0.25 - 0.4
0.10
0.25 - 0.4
0.05
0,10
Magnesium [mmol/kg/d]
0.1
0.10
0.1
0.05
0,10
Chloride [mmol/kg/d]
2 - 4
1.58
2 - 4
0.82
1.58
Phosphate [mmol/kg/d]
0.2 - 0.7
0.25
0.2 - 0.7
0.13
0.25
Acute phase = resuscitation phase when the patient requires vital organ support (sedation, mechanical ventilation, vasopressors, fluid resuscitation); Stable phase = patient is stable on, or can be weaned, from this vital support; Recovery phase = patient who is mobilizing.
For children, it might be necessary to start the nutritional therapy with half of the target dosage. The dosage should be increased stepwise according to the individual metabolic capacity up the maximum dosage.
Maximum infusion rate
According to the paediatric guidelines the maximum infusion rate depends not only on age but also on the medical condition (acute, stable and recovery phase) of the paediatric patient.
For Lipoflex peri, in the age group 2 to 12 years the glucose infusion rate is the limiting factor in the acute and stable phase, and the amino acid infusion rate in the recovery phase.
In the age group 12 to 18 years the glucose infusion rate limits the maximum infusion rate in all medical conditions.
The resulting maximum hourly infusions rates are given in the table below.
Paediatric age group
2 to 12 years
12 to 18 years
Recommended
Lipoflex peri
Recommended
Lipoflex Peri
Acute phase
Stable Phase
Recovery phase
Acute phase
Stable Phase
Recovery phase
Maximum infusion rate [ml/kg/h]
1.41
2.81
3.13
0.94
1.88
2.81
corresponding to
corresponding to
Amino acids [g/kg/h]
≤ 0.1
0.045
0.09
0.100
≤ 0.1
0.03
0.06
0.09
Glucose [g/kg/h]
Acute phase
0.09
0.09
-
-
0.03 – 0.06
0.06
-
-
Stable phase
0.09 - 0.18
-
0.18
-
0.06 – 0.12
-
0.12
-
Recovery phase
0.18 - 0.24
-
-
0.20
0.12 – 0.18
-
-
0.18
Lipids [g/kg/h]
≤ 0.15
0.056
0.112
0.125
≤ 0.15
0,038
0.075
0.112
Patients with renal/hepatic impairment
The doses should be adjusted individually in patients with hepatic or renal insufficiency (see also section 4.4).
Duration of treatment
The duration of treatment for the indications stated should not exceed 7 days. During the administration of Lipoflex peri it is necessary to provide an appropriate amount of trace elements and vitamins.
Duration of infusion of one single bag
The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h.
Method of administration
Intravenous use. Infusion into a peripheral or central vein.
● hypersensitivity to the active substances, to egg, peanut or soya protein or to any of the excipients listed in section 6.1
● inborn errors of amino acid metabolism
● severe hypertriglyceridaemia (≥ 1000 mg/dl or 11.4 mmol/l)
● severe coagulopathy
● hyperglycaemia not responding to insulin doses of up to 6 units insulin/hour
● acidosis
● intrahepatic cholestasis
● severe hepatic insufficiency
● severe renal insufficiency in absence of renal replacement therapy
● aggravating haemorrhagic diatheses
● acute thrombo-embolic events, lipid embolism
On account of its composition, this medicinal product must not be used in newborn infants, infants and toddlers under 2 years of age.
General contraindications to parenteral nutrition include:
● unstable circulatory status with vital threat (states of collapse and shock)
● acute phases of cardiac infarction and stroke
● unstable metabolic condition (e.g. severe postaggression syndrome, coma of unknown origin)
● inadequate cellular oxygen supply
● disturbances of the electrolyte and fluid balance
● acute pulmonary oedema
● decompensated cardiac insufficiency
Caution should be exercised in cases of increased serum osmolarity.
Disturbances of the fluid, electrolyte or acid-base balance must be corrected before the start of infusion.
Too rapid infusion can lead to fluid overload with pathological serum electrolyte concentrations, hyperhydration and pulmonary oedema.
Any sign or symptom of anaphylactic reaction (such as fever, shivering, rash or dyspnoea) should lead to immediate interruption of the infusion.
The serum triglyceride concentration should be monitored when infusing this medicinal product.
Depending on the patient's metabolic condition, occasional hypertriglyceridaemia may occur. If the plasma triglyceride concentration exceeds 4.6 mmol/l (400 mg/dl) during administration of lipids, it is recommended to reduce the infusion rate. The infusion must be interrupted if the plasma triglyceride concentration exceeds 11.4 mmol/l (1000 mg/dl), as these levels have been associated with acute pancreatitis.
Patients with impaired lipid metabolism
This medicinal product should be administered cautiously to patients with disturbances of lipid metabolism with increased serum triglycerides, e.g. renal insufficiency, diabetes mellitus, pancreatitis, impaired hepatic function, hypothyroidism (with hypertriglyceridaemia), sepsis, and metabolic syndrome. If this medicinal product is given to patients with these conditions, more frequent monitoring of serum triglycerides is necessary to assure triglyceride elimination and stable triglyceride levels below 11.4 mmol/l (1000 mg/dl).
In combined hyperlipidaemias and in metabolic syndrome, triglyceride levels react to glucose, lipids and overnutrition. Adjust dose accordingly. Assess and monitor other lipid and glucose sources, and drugs interfering with their metabolism.
The presence of hypertriglyceridaemia 12 hours after lipid administration also indicates a disturbance of lipid metabolism.
Like all solutions containing carbohydrates, the administration of this medicinal product can lead to hyperglycaemia. The blood glucose level should be monitored. If there is hyperglycaemia, the rate of infusion should be reduced or insulin should be administered. If the patient is receiving other intravenous glucose solutions concurrently, the amount of additionally administered glucose has to be taken into account.
An interruption of administration of the emulsion may be indicated if the blood glucose concentration rises to above 14 mmol/l (250 mg/dl) during administration.
Refeeding or repletion of malnourished or depleted patients may cause hypokalaemia, hypophosphataemia and hypomagnesaemia. Adequate supplementation of electrolytes according to deviations from normal values is necessary.
Controls of the serum electrolytes, the water balance, the acid-base balance, and of blood cell counts, coagulation status, hepatic and renal function are necessary.
Substitution of electrolytes, vitamins and trace elements may be necessary as required. As Lipoflex peri contains zinc, magnesium, calcium and phosphate, care should be taken when it is co-administered with solutions containing these substances.
This medicinal product is a preparation of complex composition. It is, therefore, strongly advisable not to add other solutions (as long as compatibility is not proven – see section 6.2).
Additions can increase the overall osmolarity of the emulsion, consider with regard to peripheral administration and monitor the injection site.
This medicinal product should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination (see also section 4.5).
As with all intravenous solutions, especially for parenteral nutrition, strict aseptic precautions are necessary for the infusion of this medicinal product.
Infusion in peripheral veins may cause thrombophlebitis. Monitor infusion site daily for signs of thrombophlebitis.
Elderly patients
Basically the same dosage as for adults applies, but caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that may frequently be associated with advanced age.
Patients with diabetes mellitus, impaired cardiac or renal function
Like all large-volume infusion solutions, this medicinal product should be administered with caution to patients with impaired cardiac or renal function.
There is only limited experience of its use in patients with diabetes mellitus or renal failure.
This medicinal product contains 1150 mg sodium per 1250 ml bag, equivalent to 58% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
The maximum daily dose of this product for a 70 kg adult is equivalent to 129% of the WHO recommended maximum daily intake for sodium.
Lipoflex peri is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
Guidelines for parenteral nutrition recommend a daily supply of 60 – 150 mmol (1.0 – 1.5 mmol/kg/d) of sodium. Lipoflex peri provides between 50 to 100 mmol of sodium.
Interference with laboratory tests
The fat content may interfere with certain laboratory measurements (e.g. bilirubin, lactate dehydrogenase, oxygen saturation) if blood is sampled before fat has been adequately cleared from the blood stream.
Some drugs, like insulin, may interfere with the body's lipase system. This kind of interaction seems, however, to be of only limited clinical importance.
Heparin given in clinical doses causes a transient release of lipoprotein lipase into the circulation. This may result initially in increased plasma lipolysis followed by a transient decrease in triglyceride clearance.
Soya-bean oil has a natural content of vitamin K1. This may interfere with the therapeutic effect of coumarin derivatives, which should be closely monitored in patients treated with such drugs.
Potassium-containing solutions like Lipoflex peri should be used with caution in patients receiving drugs that increase serum potassium concentration, such as potassium-sparing diuretics (triamterene, amiloride, spironolactone), ACE inhibitors (e.g. captopril, enalapril), angiotensin-II-receptor antagonists (e.g. losartan, valsartan), ciclosporin and tacrolimus.
Corticosteroids and ACTH are associated with sodium and fluid retention.
This medicinal product should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination (see also section 4.4).
Pregnancy
There are no or limited amount of data from the use of Lipoflex peri in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Parenteral nutrition may become necessary during pregnancy. Lipoflex peri should only be given to pregnant women after careful consideration.
Breast-feeding
Components/metabolites of Lipoflex peri are excreted in human milk, but at therapeutic doses no effects on the breastfed newborns/infants are anticipated. Nevertheless, breast-feeding is not recommended for mothers on parenteral nutrition.
Fertility
No data from the use of this medicinal product is available.
Lipoflex peri has no or negligible influence on the ability to drive and use machines.
Under conditions of correct use, in terms of dosing monitoring, observation of safety restrictions and instructions, undesirable effects may still occur. The following listing includes a number of systemic reactions that may be associated with the use of Lipoflex peri.
Undesirable effects are listed according to their frequencies as follows:
Very common
(≥ 1/10)
Common
(≥ 1/100 to < 1/10)
Uncommon
(≥ 1/1,000 to < 1/100)
Rare
(≥ 1/10,000 to < 1/1,000)
Very rare
(< 1/10,000)
Not known
(frequency cannot be estimated from the available data)
Blood and lymphatic system disorders
Rare:
Hypercoagulation
Not known:
Leucopenia, thrombocytopenia
Immune system disorders
Rare:
Allergic reactions (e.g. anaphylactic reactions,dermal eruptions, laryngeal, oral and facial oedema)
Metabolism and nutrition disorders
Uncommon:
Loss of appetite
Very rare:
Hyperlipidaemia, hyperglycaemia, metabolic acidosis The frequency of these undesirable effects is dose-dependent and may be higher under the condition of absolute or relative lipid overdose.
Nervous system disorders
Rare:
Headache, drowsiness
Vascular disorders
Rare:
Hypertension or hypotension, flush
Respiratory, thoracic and mediastinal disorders
Rare:
Dyspnoea, cyanosis
Gastrointestinal disorders
Uncommon:
Nausea, vomiting
Hepatobiliary disorders
Not known:
Cholestasis
Skin and subcutaneous tissue disorders
Rare:
Erythema, sweating
Musculoskeletal and connective tissue disorders
Rare:
Pain in the back, bones, chest and lumbar region
General disorders and administration site conditions
Common:
After a few days, vein irritation, phlebitis or thrombophlebitis may occur.
Rare:
Elevated body temperature, feeling cold, chills
Very rare:
Fat overload syndrome (details see below)
If signs of vein wall irritation, phlebitis or thrombophlebitis occur, change of the infusion site should be considered.
Should adverse reactions occur, the infusion must be stopped.
Should the triglyceride level rise to above 11.4 mmol/l (1000 mg/dl) during infusion, the infusion must be stopped. With levels above 4.6 mmol/l (400 mg/dl), the infusion may be continued at a reduced dosage (see section 4.4).
If the infusion is restarted, the patient should be carefully monitored, especially at the beginning, and serum triglycerides should be determined at short intervals.
Information on particular undesirable effects
Nausea, vomiting and lack of appetite are symptoms often related to conditions for which parenteral nutrition is indicated, and may be associated with parenteral nutrition at the same time.
Fat overload syndrome
Impaired capacity to eliminate triglycerides can lead to 'fat overload syndrome', which may be caused by overdose. Possible signs of metabolic overload must be observed. The cause may be genetic (individually different metabolism) or the fat metabolism may be affected by ongoing or previous illnesses. This syndrome may also appear during severe hypertriglyceridaemia, even at the recommended infusion rate, and in association with a sudden change in the patient's clinical condition such as renal function impairment or infection. The fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly with or without icterus, splenomegaly, anaemia, leucopenia, thrombocytopenia, coagulation disorder, haemolysis and reticulocytosis, abnormal liver function tests and coma. The symptoms are usually reversible if the infusion of the fat emulsion is discontinued.
Should signs of a fat overload syndrome occur, the infusion of this medicinal product should be discontinued immediately.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms of fluid and electrolyte overdose
Hyperhydration, electrolyte imbalance and pulmonary oedema.
Symptoms of amino acid overdose
Renal amino acid losses with consecutive amino acid imbalances, sickness, vomiting and shivering.
Symptoms of glucose overdose
Hyperglycaemia, glucosuria, dehydration, hyperosmolality, hyperglycaemic-hyperosmolar coma.
Symptoms of lipid overdose
See section 4.8.
Treatment
Immediate cessation of infusion is indicated for overdose. Further therapeutic measures depend on the particular symptoms and their severity. When infusion is recommenced after the symptoms have declined, it is recommended that the infusion rate be raised gradually with monitoring at frequent intervals.
Ask anything about Lipoflex peri emulsion for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.